Luanne Metz
#149,662
Most Influential Person Now
Researcher
Luanne Metz's AcademicInfluence.com Rankings
Luanne Metzphilosophy Degrees
Philosophy
#11148
World Rank
#15308
Historical Rank
Logic
#7948
World Rank
#9887
Historical Rank
Luanne Metzbiology Degrees
Biology
#14916
World Rank
#18794
Historical Rank
Neuroscience
#2666
World Rank
#2736
Historical Rank
Download Badge
Philosophy Biology
Why Is Luanne Metz Influential?
(Suggest an Edit or Addition)According to Wikipedia, Luanne Metz is a Canadian politician and clinical neurologist and researcher. She was elected member of the Legislative Assembly of Alberta for Calgary-Varsity in the 2023 Alberta general election. She is known for her work in the field of multiple sclerosis and has been recognized globally as an expert in the field.
Luanne Metz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005) (5003)
- A full genome search in multiple sclerosis (1996) (709)
- The promise of minocycline in neurology (2004) (481)
- Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. (2002) (430)
- Major depression in multiple sclerosis (2003) (352)
- Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. (2013) (351)
- A comparison of health utility measures for the evaluation of multiple sclerosis treatments (2004) (202)
- Long-Term Medical Conditions and Major Depression: Strength of Association for Specific Conditions in the General Population (2005) (184)
- Regional variation of multiple sclerosis prevalence in Canada (2005) (169)
- Minocycline reduces gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis (2004) (169)
- Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population (2000) (165)
- Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators (2007) (165)
- Epigenetic changes in patients with multiple sclerosis (2013) (117)
- Devic's Neuromyelitis Optica Treated with Intravenous Gamma Globulin (IVIG) (2004) (113)
- Additive effect of the combination of glatiramer acetate and minocycline in a model of MS (2005) (106)
- Major Depression and Quality of Life in Individuals with Multiple Sclerosis (2000) (105)
- Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis (2017) (104)
- Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. (2005) (103)
- Psychotic disorders in MS: Population-based evidence of an association (2005) (102)
- Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis (2001) (100)
- The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. (2018) (95)
- Randomized multicenter trial of natalizumab in acute MS relapses (2004) (91)
- MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group (2002) (91)
- The effect of immunomodulatory treatment on multiple sclerosis fatigue (2004) (90)
- Interferon β-1a and depression in relapsing - remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial (2001) (89)
- Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS (2018) (81)
- Effective combination of minocycline and interferon-β in a model of multiple sclerosis (2005) (78)
- Validity of four screening scales for major depression in MS (2015) (78)
- Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results (2008) (76)
- Interferon &bgr;1a and depression in secondary progressive MS: Data from the SPECTRIMS Trial (2002) (75)
- Depression in multiple sclerosis: A long-term longitudinal study (2015) (74)
- Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. (2016) (72)
- Pilot Study of Minocycline in Relapsing-Remitting Multiple Sclerosis (2008) (71)
- Depressive symptoms in a treated multiple sclerosis cohort (2003) (68)
- Evaluation of the 9–Item Patient Health Questionnaire (PHQ–9) as an Assessment Instrument for Symptoms of Depression in Patients with Multiple Sclerosis (2012) (63)
- The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis (2005) (62)
- Environmental factors and their regulation of immunity in multiple sclerosis (2012) (61)
- Depression in multiple sclerosis. (1997) (60)
- IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. (2004) (59)
- Urinary tract infections may trigger relapse in multiple sclerosis. (1998) (58)
- Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis. (2017) (57)
- The association of depression with disease course in multiple sclerosis (2005) (55)
- Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients (1998) (53)
- Adherence of adolescents to multiple sclerosis disease-modifying therapy. (2009) (52)
- Retinal Nerve Fiber Layer and Future Risk of Multiple Sclerosis (2008) (51)
- Clinical correlates of CES-D depressive symptom ratings in an MS population. (2005) (49)
- Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic (2017) (48)
- T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis (2009) (48)
- Genetic susceptibility to MS: a second stage analysis in Canadian MS families (2001) (47)
- Prolactin in multiple sclerosis (2013) (46)
- Posterior fossa lesion volume and slowed information processing in multiple sclerosis. (2004) (45)
- Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. (2007) (45)
- Corticosteroids for multiple sclerosis: I. Application for treating exacerbations (2007) (45)
- A Quantitative Analysis of Suspected Environmental Causes of MS (2011) (45)
- Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome (2018) (44)
- The use of complementary and alternative therapies by people with multiple sclerosis. (2003) (43)
- Treatment trials in progressive MS—current challenges and future directions (2013) (42)
- Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. (2013) (42)
- The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results (2014) (41)
- Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair (2013) (41)
- Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity (2020) (40)
- Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis (2002) (40)
- Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis (2015) (40)
- Reduction of microglial activity in a model of multiple sclerosis by dipyridamole (2013) (39)
- Experimental models of neuroprotection relevant to multiple sclerosis (2007) (38)
- Foreign Accent Syndrome in a Patient with Multiple Sclerosis (2004) (36)
- Challenges in screening for depression in multiple sclerosis (2010) (35)
- Deep Learning of Brain Lesion Patterns for Predicting Future Disease Activity in Patients with Early Symptoms of Multiple Sclerosis (2016) (35)
- Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. (2010) (34)
- Multiple sclerosis: symptomatic therapies. (1998) (34)
- Prevalence of Multiple Sclerosis in First Nations People of Alberta (2007) (33)
- Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease? (2018) (33)
- Point prevalence and correlates of depression in a national community sample with multiple sclerosis. (2014) (32)
- Ethics of placebo-controlled clinical trials in multiple sclerosis (2008) (31)
- 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing–remitting multiple sclerosis: A 3-year pilot study (2010) (29)
- Association of &agr;-Synuclein Immunoreactivity With Inflammatory Activity in Multiple Sclerosis Lesions (2009) (29)
- Descriptive Epidemiology of Affective Disorders in Multiple Sclerosis (2005) (27)
- Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. (2009) (27)
- Deep learning of brain lesion patterns and user-defined clinical and MRI features for predicting conversion to multiple sclerosis from clinically isolated syndrome (2019) (26)
- Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study (2015) (26)
- Hopelessness Ratings in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis (2002) (24)
- Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial (2002) (24)
- Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis (2015) (23)
- Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial (2021) (22)
- Fatigue and depression in multiple sclerosis. (2000) (21)
- Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: A preliminary study (2011) (21)
- Glatiramer acetate therapy for multiple sclerosis: a review (2006) (21)
- Disease Management for Depression in an Ms Clinic (2007) (21)
- Incidence of Multiple Sclerosis among First Nations People in Alberta, Canada (2006) (20)
- A Double‐Blind, Randomized, Placebo‐Controlled Trial of Cranberry Supplements in Multiple Sclerosis (2002) (19)
- The case for vitamin D supplementation in multiple sclerosis. (2013) (18)
- Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring (2015) (18)
- Hand dexterity and direct disease related cost in multiple sclerosis (2014) (17)
- The natural history of early versus late disability accumulation in primary progressive MS (2014) (16)
- Symptomatic therapies of multiple sclerosis. (1999) (16)
- Gestational bisphenol-A exposure lowers the threshold for autoimmunity in a model of multiple sclerosis (2017) (15)
- The promise of futility trials in neurological diseases (2015) (15)
- CRYAB modulates the activation of CD4+ T cells from relapsing–remitting multiple sclerosis patients (2013) (14)
- 1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis (2015) (14)
- The impact of resilience on healthy aging with multiple sclerosis (2020) (14)
- Depression as a predictor of occupational transition in a multiple sclerosis cohort. (2013) (14)
- Sensory Temporal Thresholds and Interhemispheric Transfer Times in Multiple Sclerosis: A Preliminary Study of a New Outcome Measure (2003) (14)
- Serum NSE level and disability progression in multiple sclerosis (2015) (13)
- Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types (2016) (13)
- Migraine and Intracerebral Hemorrhage (1989) (13)
- Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent (2020) (12)
- Multiple sclerosis-related fatigue: the role of impaired corticospinal responses and heightened exercise fatigability. (2020) (12)
- Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? (2003) (11)
- Global transcriptome profiling of mild relapsing‐remitting versus primary progressive multiple sclerosis (2018) (11)
- Health Status, Stress and Life Satisfaction in a Community Population with MS (2012) (11)
- Hydroxychloroquine for Primary Progressive Multiple Sclerosis (2021) (11)
- Perceived met and unmet health-care needs in a community population with multiple sclerosis. (2012) (11)
- Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy (2002) (11)
- Long noncoding RNAs associated with phenotypic severity in multiple sclerosis. (2019) (11)
- Corpus Callosum Volume and Interhemispheric Transfer in Multiple Sclerosis (2010) (10)
- Affective Disorders in Motor Neuron Disease: A Population-Based Study (2006) (10)
- Major Depressive Disorder and Health Care Costs in Multiple Sclerosis (2002) (10)
- Texture Analysis of MR Images of Minocycline Treated MS Patients (2003) (10)
- MR Multi-Spectral Texture Analysis Using Space-Frequency Information (2004) (10)
- MRI texture heterogeneity in the optic nerve predicts visual recovery after acute optic neuritis☆ (2014) (10)
- Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study (2016) (9)
- Detection of reduced interhemispheric cortical communication during task execution in multiple sclerosis patients using functional near-infrared spectroscopy (2014) (9)
- A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder. (2021) (8)
- Disability in a Community Population with MS with and without Mental Disorders (2012) (8)
- Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif (R)): 24-week results of a phase IIIb study (2006) (8)
- Discriminative ability of quality of life measures in multiple sclerosis (2017) (8)
- Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis. (2019) (7)
- Hospitalization is associated with subsequent disability in multiple sclerosis. (2017) (7)
- Repurposing Domperidone in Secondary Progressive Multiple Sclerosis (2021) (7)
- Smoking does not influence disability accumulation in primary progressive multiple sclerosis (2017) (7)
- Effective treatment of progressive MS remains elusive (2018) (6)
- Advanced Analysis of Diffusion Tensor Imaging Along With Machine Learning Provides New Sensitive Measures of Tissue Pathology and Intra-Lesion Activity in Multiple Sclerosis (2021) (6)
- Identifying reliable change in tactile temporal thresholds in multiple sclerosis: test-retest reliability (2006) (6)
- Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis (2019) (6)
- Association of > -Synuclein Immunoreactivity With Inflammatory Activity in Multiple Sclerosis Lesions (2009) (5)
- Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers (2022) (4)
- Changes in tissue directionality reflect differences in myelin content after demyelination in mice spinal cords. (2014) (4)
- Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis (2018) (4)
- Responding to Reported Clusters of Common Diseases: The Case of Multiple Sclerosis (1997) (4)
- FLAIR2 improves LesionTOADS automatic segmentation of multiple sclerosis lesions in non-homogenized, multi-center, 2D clinical magnetic resonance images (2019) (4)
- Immunogenicity of Rebif (R) New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis: results from a phase IIIb study (2008) (3)
- Nonlesional diffusely abnormal appearing white matter in clinically isolated syndrome: Prevalence, association with clinical and MRI features, and risk for conversion to multiple sclerosis (2021) (3)
- Tactile temporal thresholds detect relapse-related changes in multiple sclerosis: a preliminary study (2005) (3)
- Ischemic Strokes in a Man with Congenital Afibrinogenemia (2018) (3)
- New criteria for the diagnosis of multiple sclerosis (2005) (2)
- Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis. (2021) (2)
- Cannabinoids and bladder symptoms in multiple sclerosis. (2021) (2)
- Symptomatic therapy for multiple sclerosis (2013) (2)
- Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case–control study (2015) (2)
- Corrigendum to “The case for vitamin D supplementation in multiple sclerosis” [Mult. Scler. Relat. Disord. 2 (2013) 281–306] (2014) (2)
- Repurposing Domperidone in Secondary Progressive MS: A Simon 2-Stage Phase 2 Futility Trial (2021) (1)
- Multiple Sclerosis Clinic Utilization is Associated with Fewer Emergency Department Visits (2021) (1)
- 7157 Preferably large fiber damage in the corpus callosum of progressive MS compared with relapsing MS and controls (2013) (1)
- Exploring Mechanisms of Multiple Sclerosis Lesion Evolution Using Advanced MRI (P4.160) (2016) (1)
- 1.5T versus 3.0T MRI texture analysis in the normal appearing white matter of multiple sclerosis patients (2011) (1)
- IIIb study in patients with relapsing multiple sclerosis : 96-week results-1 a ( Rebif ® New Formulation ) in a Phase β Safety and immunogenicity of a new formulation of interferon (2009) (1)
- Quality of life, respiratory symptoms, and health care utilization 1 year following outpatient management of COVID-19: a prospective cohort study (2022) (1)
- Safety and tolerability of Rebif((R)) New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis: results from a phase IIIb study (2008) (1)
- Reduction of microglial activity in a model of multiple sclerosis by dipyridamole (2013) (1)
- Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica (P4.001) (2014) (1)
- The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design (2021) (1)
- An enrichment strategy for clinical trials in SPMS (2021) (1)
- Reliability of Visual Temporal Thresholds (2007) (0)
- Minocycline in neurological diseases – Authors' reply (2005) (0)
- Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MS (2023) (0)
- OPTIMIZING VITAMIN D LEVELS IN PATIENTS WITH MULTIPLE SCLEROSIS (2008) (0)
- For peer review only The Canadian Survey of Health, Lifestyle and Aging with Multiple Sclerosis; Methodology and Initial Results (2014) (0)
- Autologous Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica - An Update (P5.259) (2015) (0)
- Chapter 21 The Psychosocial Consequences of Multiple Sclerosis (2003) (0)
- Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate. (2023) (0)
- Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials (2023) (0)
- Subject Index Vol. 66, 1997 (1997) (0)
- Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic (2017) (0)
- Gestational exposure to bisphenol-A increases susceptibility of adult mice to development of EAE (2014) (0)
- How Semantics Connotations May Influence Concerns About Donation of Biospecimens (2020) (0)
- Prediction of persistent and transient T1 'black holes' in multiple sclerosis using MRI texture analysis (2009) (0)
- Randomized Trial of Minocycline for Clinically Isolated Syndrome and Early Single Relapse Multiple Sclerosis: Study Design, Participant Characteristics, and Recruitment Challenges (P1.227) (2014) (0)
- OBSERVATION Continued Disease Activity in a Patient With Multiple Sclerosis After Allogeneic Hematopoietic Cell Transplantation (2008) (0)
- Baseline T 2 MRI texture predicts visual recovery in patients with acute optic neuritis (2010) (0)
- 361: The Incidence of Multiple Sclerosis Among First Nations People in Alberta, Canada (2005) (0)
- Multiple sclerosis (MS) is a recurrent inflammation of the central nervous system white matter leading to myelin (2003) (0)
- Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: Changes in Treatment Patterns and Opinions in a Province-Wide Study (P05.183) (2013) (0)
- Late Breaking News (2015) (0)
- Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels (2022) (0)
- Time for a Population Based Approach to Multiple Sclerosis Care (2007) (0)
- Safety and immunogenicity of interferon beta-1a (Rebif (R) New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 48-week results (2007) (0)
- Advanced diffusion MRI and image texture analysis detect widespread brain structural differences between relapsing-remitting and secondary progressive multiple sclerosis (2022) (0)
- MRI spectra detect myelin differences between types of multiple sclerosis lesions (2018) (0)
- 0599 The incidence of Multiple Sclerosis among first nations people in Alberta, Canada (2005) (0)
- Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis (2015) (0)
- Expression of risk genes linked to vitamin D receptor super-enhancer regions and their association with phenotype severity in multiple sclerosis (2022) (0)
This paper list is powered by the following services:
Other Resources About Luanne Metz
What Schools Are Affiliated With Luanne Metz?
Luanne Metz is affiliated with the following schools:
